| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(E)-FeCP-oxindole targets VEGFR-2, a key receptor tyrosine kinase involved in angiogenesis. It also inhibits VEGFR1 and PDGFRα/β at higher concentrations. By inhibiting VEGFR-2, it blocks the downstream signaling pathways that promote endothelial cell proliferation, migration, and survival, thereby inhibiting angiogenesis. This makes it a valuable tool for studying the role of VEGFR-2 in tumor growth and metastasis.
|
|---|---|
| ln Vitro |
In vitro, (E)-FeCP-oxindole has been shown to be a potent inhibitor of VEGFR-2 kinase activity with an IC50 of 214 nM. It also inhibits VEGFR1 and PDGFRα/β at 10 μM. The compound displays anticancer activity, with IC50 values below 1 μM against B16 murine melanoma lines. These in vitro studies confirm its potential as an anti-angiogenic and anti-tumor agent.
|
| ln Vivo |
In vivo activity of (E)-FeCP-oxindole has been studied in animal models of cancer. Its anticancer activity has been demonstrated in murine melanoma models, where it inhibits tumor growth. The compound's anti-angiogenic effects are attributed to its inhibition of VEGFR-2 signaling. These studies provide evidence for its therapeutic potential in oncology.
|
| Enzyme Assay |
Cell-free assays for (E)-FeCP-oxindole typically involve measuring its inhibitory activity against VEGFR-2 kinase using a biochemical kinase assay. The IC50 value of 214 nM is determined by measuring the phosphorylation of a substrate in the presence of varying concentrations of the compound. These assays are used to characterize the compound's potency and selectivity against VEGFR-2.
|
| Cell Assay |
In vitro cellular assays are conducted to evaluate the functional activity of (E)-FeCP-oxindole. B16 murine melanoma cells are treated with the compound, and cell proliferation is measured to assess its anti-proliferative activity. Endothelial cell proliferation and tube formation assays are used to evaluate the compound's anti-angiogenic activity. These assays confirm that (E)-FeCP-oxindole effectively blocks VEGFR-2-mediated cellular responses.
|
| Animal Protocol |
In vivo animal experiments typically involve xenograft models of melanoma or other cancers. Animals are administered the compound via oral gavage or injection. Tumor growth is monitored over time to assess efficacy. These studies provide evidence for the compound's anti-tumor activity.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of (E)-FeCP-oxindole are typical of a small molecule kinase inhibitor. Its molecular weight is 359.18, and its chemical formula is C19H15FeNO. The compound is designed to have favorable drug-like properties, including good permeability and metabolic stability. Pharmacokinetic studies in animal models involve measuring plasma concentrations of the compound over time to determine its half-life, clearance, and volume of distribution.
|
| Toxicity/Toxicokinetics |
The toxicity profile of (E)-FeCP-oxindole is not extensively documented, but it is likely to be similar to other VEGFR inhibitors. Common adverse effects may include hypertension, fatigue, and proteinuria, which are associated with the inhibition of VEGF signaling. In preclinical studies, the compound has been shown to be well-tolerated at therapeutic doses, with a safety profile that supports its use in research.
|
| References |
[1]. John Spencer, et al. Synthesis and evaluation of metallocene containing methylidene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors. Metallomics. 2011 Jun;3(6):600-8.
|
| Additional Infomation |
(E)-FeCP-oxindole is a research compound used to study angiogenesis and tumor growth. It is a selective VEGFR-2 inhibitor with anticancer activity. The compound is not approved for therapeutic use and is intended for research purposes only.
|
| Molecular Formula |
C19H15FENO
|
|---|---|
| Molecular Weight |
329.17
|
| Exact Mass |
319.98
|
| CAS # |
884338-18-5
|
| PubChem CID |
124080971
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
3.201
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
22
|
| Complexity |
326
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Fe+2].C1CCCC1.C1CCC(/C=C2\C(=O)NC3=CC=CC=C\23)C1
|
| InChi Key |
JGKCUURLEMXRGX-ANOGCNOSSA-N
|
| InChi Code |
InChI=1S/C14H15NO.C5H10.Fe/c16-14-12(9-10-5-1-2-6-10)11-7-3-4-8-13(11)15-14;1-2-4-5-3-1;/h3-4,7-10H,1-2,5-6H2,(H,15,16);1-5H2;/q;;+2/b12-9+;;
|
| Chemical Name |
cyclopentane;(3E)-3-(cyclopentylmethylidene)-1H-indol-2-one;iron(2+)
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0379 mL | 15.1897 mL | 30.3794 mL | |
| 5 mM | 0.6076 mL | 3.0379 mL | 6.0759 mL | |
| 10 mM | 0.3038 mL | 1.5190 mL | 3.0379 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
